The Eosinophilia-Myalgia Syndrome (EMS) is a recently reorganized disorder in patients ingesting pharmacologic doses of L-tryptophan. We studied the lesions of skeletal muscle, peripheral nerve and skin in 12 cases of EMS. Perimyositis was severe in four, moderate in two, mild in three and absent in three cases. The lesions contained many eosinophils, T-helper cells, mast cells and activated macrophages. Type 2 myofiber atrophy was present in five cases and in one, this was the only pathologic finding. Severe epineurial inflammation was seen in the three sural nerve biopsies. Indirect evidence for peripheral neurologic involvement in three other cases consisted of inflammation surrounding intramuscular nerve twigs (two cases) and neurogenic atrophy (one case). Phlebitis accompanied the connective tissue inflammation in five cases and endarteritis in one. Fasciitis was present in three of four skin biopsies and dermal fibrosis in one.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00005072-199101000-00004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.
Allergol Select
October 2024
Center for Child and Adolescent Health, Helios Hospital Krefeld, Academic Hospital of RWTH Aachen, Krefeld.
Article Synopsis
- Primary atopic disorders (PAD) are rare genetic conditions caused by specific gene variants that affect skin and immune function, making diagnosis challenging among common allergic disease cases.
- Identifying PAD requires recognizing clinical red flags like family history and unusual infections, as conventional lab tests are inadequate for definitive diagnosis.
- Whole-genome sequencing (WGS) enhances diagnostic efficiency and accuracy, but requires careful interpretation and collaboration among specialists to effectively manage PAD cases.
Eosinophilia-myalgia syndrome presenting with overlapping features of eosinophilic fasciitis and sarcoidal granulomas.
JAAD Case Rep
August 2024
Department of Dermatology, University of Utah, Salt Lake City, Utah.
Toxicology and safety study of L-tryptophan and its impurities for use in swine.
J Appl Toxicol
August 2024
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Article Synopsis
- * A study was conducted on pigs to evaluate the potential risks of using L-tryptophan as a feed additive, focusing on general toxicity and EMS-related symptoms.
- * Results showed no toxic effects or EMS symptoms in the pigs, indicating that L-tryptophan and its impurities do not pose safety concerns, allowing its continued use in swine diets throughout all growth stages.
B-cell acute lymphoblastic leukemia associated with hypereosinophilia: a case report and brief literature review.
SAGE Open Med Case Rep
January 2024
Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
Article Synopsis
- B-cell acute lymphoblastic leukemia (B-ALL) associated with eosinophilia (ALL-eo) is a rare condition, typically marked by the absence of blast cells in peripheral blood and symptoms like rash, fever, and dyspnea.
- A 16-year-old male presented with generalized itching and urticaria; blood tests showed 90% eosinophils but no blasts.
- Diagnosis was confirmed through a bone marrow examination revealing lymphoid blasts, and the patient was treated with the Berlin-Frankfurt-Münster chemotherapy regimen.
Dupilumab suppresses relapsing chronic eosinophilic pneumonia with severe asthma.
Nagoya J Med Sci
November 2023
Department of Respirology, National Hospital Organization Yokohama Medical Center, Yokohama, Japan.
Article Synopsis
- Dupilumab blocks the IL-4/IL-13 pathway, leading to increased eosinophils in the blood, which can potentially contribute to chronic eosinophilic pneumonia (CEP) but no direct link has been established.
- A 33-year-old woman with a history of asthma and previous CEP experienced multiple asthma exacerbations and a recurrence of CEP despite steroid treatment.
- After starting dupilumab, her asthma symptoms improved significantly, and she didn't experience any further asthma exacerbations or CEP relapses over a 12-month period, suggesting it may be an effective option for similar patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!